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Abstract: Zoledronic acid is a nitrogen-containing, third-generation bisphosphonate that 
has recently been approved for the treatment of postmenopausal osteoporosis as an annual 
intravenous infusion. Zoledronic acid is an antiresorptive agent which has a high afﬁ  nity for 
mineralized bone and especially for sites of high bone turnover. Zoledronic acid is excreted 
by the kidney without further metabolism. Zoledronic acid administered as a 5 mg intravenous 
infusion annually increases bone mineral density in the lumbar spine and femoral neck by 6.7% 
and 5.1% respectively and reduces the incidence of new vertebral and hip fractures by 70% and 
41% respectively in postmenopausal women with osteoporosis. Most common side effects are 
post-dose fever, ﬂ  u-like symptoms, myalgia, arthralgia, and headache which usually occur in 
the ﬁ  rst 3 days after infusion and are self-limited. Rare adverse effects include renal dysfunc-
tion, hypocalcemia, atrial ﬁ  brillation, and osteonecrosis of the jaw.
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Introduction
Osteoporosis is characterized by low bone mass and abnormal bone quality which 
lead to decreased bone strength and increased susceptibility to fractures (Consensus 
Development Conference 1993). According to the World Health Organization (WHO) 
and the European Foundation for Osteoporosis and Bone Disease (Kanis et al 1997), 
the deﬁ  nition of osteoporosis is based on the measurement of bone mineral density 
(BMD) using the T-score. The T-score represents the number of standard deviations 
from the peak bone mass in healthy adults at the age of 30. Osteoporosis is deﬁ  ned by 
a T-score equal to or greater than –2.5, which is the reference point used in clinical 
trials. Osteopenia is deﬁ  ned by a T-score between –1 and –2.5. Osteoporosis is one 
of the most common health problems in postmenopausal women with great socio-
economic importance. Using the WHO criteria, 34%–50% of US women 50 years 
have osteopenia and 17%–20% suffer from osteoporosis (Looker et al 1995; Siris 
et al 2001).
Bisphosphonates have demonstrated efﬁ  cacy in reducing vertebral and nonvertebral 
fracture risk (Lambrinoudaki et al 2006). They are pyrophosphate analogues that 
have been modiﬁ  ed to act as bone-speciﬁ  c anti-resorptive agents by exerting a potent 
inhibitory effect on osteoclasts. Thus, they reduce bone turnover, increase BMD, and 
decrease fracture risk both at the lumbar spine and the hip. Bisphosphonates have a 
high afﬁ  nity for bone surfaces, where they accumulate, and due to this selectivity of 
action they lack systemic side-effects. Alendronate and risedronate are administered 
orally either daily or once weekly, while ibandronate is a newer third-generation 
bisphosphonate administered once monthly with similar efﬁ  cacy for BMD and 
for markers of bone remodeling. The main adverse effect is upper gastrointestinal Clinical Interventions in Aging 2008:3(3) 446
Lambrinoudaki et al
irritation, which together with the strict dosing schedule 
for oral bisphosphonates, represent major reasons for poor 
compliance. Therefore, new intravenous (IV) therapies have 
been developed that allow dosing at very long intervals, 
which should improve adherence to therapy.
Chemistry
Zoledronic acid is a nitrogen-containing bisphosphonate. Its 
main structure has a phosphorus-carbon-phosphorus core with 
a hydroxyl group attached to the R1 position (Green 2001). 
A heterocyclic imidazole group is attached to the R2 position 
and differentiates zoledronic acid from other bisphosphonates, 
concerning the chemical structure (Widler et al 2002).
Mechanism of action
Zoledronic acid is a potent inhibitor of bone resorption. 
It inhibits osteoclast proliferation (Coxon et al 2000) and 
induces osteoclast apoptotic cell death (Benford et al 2001). 
Its potency results from its high afﬁ  nity for mineralized bone 
and especially for sites of high bone turnover (Nancollas 
et al 2006). Zoledronic acid inhibits farnesyl diphosphate 
(FPP) synthase and in addition the cellular biosynthetic, FPP 
synthase-mediated mevalonate pathway (Benford et al 2001). 
In the absence of FPP synthase, FPP and geranylgeranyl 
diphosphate are not produced, which results in the inhibition 
of the GTP-binding proteins prenylation in osteoclasts. Low 
levels of prenylated GTP-binding proteins inhibit osteoclast 
activity and induce osteoclast apoptosis (Boissier et al 2000; 
Benford et al 2001; Green 2001). Furthermore, zoledronic 
acid may boost osteoblast differentiation and increase bone 
mineralization (Reinholz et al 2000).
Pharmacokinetics
Zoledronic acid is not metabolized in humans and is excreted 
intact in the urine. It has minor or no effects on the cyto-
chrome P450 enzyme system and therefore has no interaction 
with the drugs metabolized via cytochrome P450.
Zoledronic acid binding to plasma proteins is 22%. 
Zoledronic acid concentration in plasma after the infusion 
decreases rapidly due to the increased absorption of the 
drug by the bone. However, small amounts of zoledronic 
acid can be detected in plasma several days after the infu-
sion, representing the drug released gradually from the bone 
during bone turn-over. In a study of pharmacokinetics and 
pharmacodynamics of zoledronic acid in cancer patients with 
bone metastases (Chen et al 2002), 24 hours after infusion the 
peak concentrations of zoledronic acid in plasma decreased 
to 1% of Cmax.
The excretion of zoledronic acid by the kidney does not 
depend on the dose or the infusion time (Chen et al 2002). The 
drug can be detected in urine in trace amounts up to 28 days 
after the infusion, although adequate amounts are present in 
urine only in the ﬁ  rst 24 hours (Chen et al 2002). The amount 
found in the urine in the ﬁ  rst 24 hours post dose, however, 
represents just the one- or two-thirds of the total dose as a 
result of the increased binding of the drug to the bone.
Indications beyond postmenopausal 
osteoporosis
Zoledronic acid is indicated for the prevention of skeletal-
related events (SREs) such as pathological fractures, bone 
pain, spinal compression, need for bone radiation, or surgery 
in patients with bone metastases, at a recommended dose of 
4 mg IV every 3–4 weeks, and for the treatment of hyper-
calcemia of malignancy (HCM) at a recommended dose of 
4 mg given as a single IV infusion. These malignancies most 
commonly include prostate cancer, breast cancer, lung cancer, 
or multiple myeloma (Perry and Figgitt 2004). Patients with 
recurrent or metastatic prostate cancer often present with bone 
loss and the androgen deprivation therapy can trigger further 
rapid BMD decreases (Smith 2006). Intermittent adminis-
tration of zoledronic acid in these patients increases BMD 
(Smith et al 2003; Ryan et al 2007), suppresses markers of 
bone turnover (Ryan et al 2007), and reduces the incidence of 
pathologic fractures and bone pain (Saad 2002). Zoledronic 
acid has also been used for the prevention of bone loss and 
fracture incidence in women with breast cancer receiving 
estrogen-depleting therapies such as aromatase inhibitors 
(Hadji 2007). Zoledronic acid improves or stabilizes bone 
density (Brufsky 2006; Gnant et al 2007) and reduces the 
frequency of skeletal-related events by 30%  –40% (Body 
2006). Monthly IV infusions of zoledronic acid have been 
shown to reduce skeletal complications among patients 
with multiple myeloma and are now a mainstay of myeloma 
therapy (Rosen et al 2001; Yeh and Berenson 2006). Treat-
ment with zoledronic acid in Paget’s disease improves 
short-term control of increased bone turnover and maintains 
a prolonged biochemical remission, making it the most effec-
tive therapy available to date (Reid et al 2005; Hosking et al 
2007). HCM is among the most common and most serious 
complications of malignancy in the late stage and occurs in 
5%–10% of all cancer patients. Zoledronic acid is effective 
and well tolerated for hypercalcemia of malignancy in a dose 
of 4 mg IV (Kenji Kawada et al 2005). The administration 
of zoledronic acid in cancer patients at intermittent doses of 
4 mg is generally well tolerated. Osteonecrosis of the jaw Clinical Interventions in Aging 2008:3(3) 447
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(ONJ) is a rare complication, mainly seen in combination with 
other risk factors such as dental surgery or trauma, concurrent 
glucocorticoids, systemic chemotherapy, local radiation, and 
malnutrition. This complication is usually observed in cancer 
patients, probably due to the repeated dosage regimen and 
the prolonged exposure. The annual dosage regimen used in 
postmenopausal osteoporosis, on the other hand, is considered 
safe with regard to the risk of ONJ. In order to minimize the 
risk a dental evaluation should be conducted before, during 
and after treatment (Wutzl et al 2006).
Efﬁ  cacy of zoledronic acid 
in the treatment of postmenpausal 
osteoporosis
Many clinical studies up to now have demonstrated the 
efﬁ  cacy of the annual intravenous infusion of zoledronic 
acid with respect to the treatment of postmenopausal osteo-
porosis.
The indication for postmenopausal osteoporosis was 
based on the HORIZON Pivotal Fracture Trial (Black 
et al 2007). This trial included 7765 patients (mean age, 
73 years) who were randomly assigned to receive either 
a single 15-minute infusion of zoledronic acid (5 mg) or 
placebo at baseline, at 12 months, and at 24 months. The 
patients were followed until 36 months. Inclusion criteria 
were lumbar spine BMD T-score less than or equal to −1.5 
and at least 2 mild or moderate existing vertebral fracture(s) 
or a femoral neck BMD T-score less than or equal to −2.5 
with or without evidence of existing vertebral fracture(s). 
Treatment with zoledronic acid reduced the risk of mor-
phometric vertebral fracture by 70% during a 3-year period, 
compared to placebo (3.3% incidence of morphometric 
vertebral fracture in the zoledronic acid group compared 
to 10.9% in the placebo group, relative risk = 0.30, 95% 
conﬁ  dence interval [CI] = 0.24–0.38). Additionally, there 
was a reduction in the risk of hip fracture by 41% (1.4% 
incidence of hip fracture in the zoledronic acid group 
and 2.5% in the placebo group, hazard ratio = 0.59, 95% 
CI = 0.42–0.83). Nonvertebral fractures, clinical fractures, 
and clinical vertebral fractures were reduced by 25%, 33%, 
and 77%, respectively (p  0.001 for all comparisons). 
Patients receiving zoledronic acid had also a signiﬁ  cant 
improvement in BMD and bone metabolism markers. The 
results of this trial indicate that a once-yearly infusion of 
zoledronic acid during a 3-year period signiﬁ  cantly reduces 
the risk of vertebral, hip, and other fractures in patients 
with postmenopausal osteoporosis. However, it should 
be taken into account that the HORIZON trial recruited 
patients who had already sustained a vertebral fracture and 
were, therefore, a selected high risk population, who might 
have shown higher rates of fracture reduction compared to 
patients without prevalent fractures.
A randomized, double-blind, double-dummy, multicenter 
trial was conducted in order to assess the safety and the efﬁ  -
cacy of a single dose of IV zoledronic acid 5 mg compared 
to oral alendronate 70 mg weekly in postmenopausal women 
with low BMD who had previously been treated with alendro-
nate (McClung et al 2007). In this trial, a single infusion of 
zoledronic acid 5 mg maintained BMD 12 months following 
the switch from oral alendronate in women with osteoporosis. 
In the zoledronic acid group, mean biomarker levels were 
reduced from baseline after 3 months, returned to baseline 
after 6 months, and increased thereafter but remained within 
the premenopausal range. On the contrary, mean biomarker 
levels in the alendronate group remained at or close to base-
line levels for the duration of the study. The overall rates of 
adverse events were comparable in both groups. Addition-
ally, bone biopsies indicated that both treatments decrease 
excessive remodeling seen in osteoporosis. More speciﬁ  cally, 
23 specimens with comparable baseline characteristics had 
adequate tissue for examination. All the specimens had nor-
mal appearance and contained adequate double tetracycline 
label, indicating that remodeling continued with both treat-
ing options. There was no evidence of marrow ﬁ  brosis and 
bone tissue appeared normal with no excess accumulation of 
unmineralized osteoid. The two treatments resulted in almost 
identical effects on static and dynamic histomorphometric 
measures. The median point estimates of activation frequency 
for the groups treated with zoledronic acid and alendronate 
were 0.08 and 0.09, respectively. This conﬁ  rms the fact that 
bone turnover is not excessively reduced with zoledronic acid 
treatment. As for the preference expressed by the participants, 
78.7% of the patients preferred the once-yearly infusion to 
weekly oral therapy. According to the above, patients can 
be safely switched from oral alendronate to zoledronic acid 
5 mg infusion with maintenance of therapeutic effect for at 
least 12 months.
In a substudy of the HORIZON pivotal fracture trial 
(Recker et al 2008) 152 patients receiving intravenous 
zoledronic acid 5 mg once-yearly underwent bone biopsy 
in order to determine effects on bone remodelling and bone 
architecture. According to this study, the zoledronic acid 
group exhibited higher trabecular bone volume (p = 0.020), 
higher trabecular numbers (p = 0.008), decreased trabecular 
separation (p = 0.011), and a trend toward improvement in Clinical Interventions in Aging 2008:3(3) 448
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connectivity density (p = 0.062) compared to the placebo 
group, all indicating better preservation of trabecular struc-
ture after treatment with zoledronic acid. Bone biopsies 
also indicate that zoledronic acid is associated with reduced 
bone turnover due to the fact that it causes reduction in 
activation frequency and also in mineralizing surface 
and volume referent bone formation rate versus placebo. 
Additionally, mineral appositional rate was improved in the 
zoledronic acid group (p = 0.0002) suggesting improved 
osteoblast function. Finally, zoledronic acid is associated 
with normal osteoid formation and mineralization of newly 
formed bone as indicated by the similar mineralization lag 
time in both groups and the lower osteoid volume (p  
0.0001) and osteoid thickness (p = 0.0094) in zoledronic 
acid-treated patients. According to the above, zoledronic 
acid favors the reduction of bone turnover and the pres-
ervation of bone structure and mass without any signs of 
adynamic bone.
A randomized, double-blind, double-dummy, multi-
center, 24-week trial (Saag et al 2007) evaluated the onset of 
action for both zoledronic acid and alendronate comparing a 
single infusion of zoledronic acid 5 mg (n = 69) to weekly oral 
alendronate 70 mg (n = 59) in postmenopausal women with 
low BMD (T-score  −2 by DXA) as assessed by reductions 
in urine N-telopeptide of type I collagen (NTX) at week 1. 
Zoledronic acid resulted in a signiﬁ  cantly greater reduction 
in urine NTX levels at week 1 compared to alendronate, sug-
gesting a more rapid onset of action (p  0.0001).
At week 1, 6 patients receiving zoledronic acid and 0 
patients receiving alendronate had NTX levels below the 
limit of detection. The zoledronic acid group had signiﬁ  -
cantly lower mean urine NTX values throughout the 24-week 
study, compared to the alendronate group. The lowest levels 
of mean urine NTX was at 1 week in the zoledronic group. 
Levels gradually increased thereafter, and remained stable 
within the study reference range for premenopausal women 
from week 12 to study end. In the alendronate group, mean 
urine NTX levels showed a more gradual reduction, reaching 
the lowest levels by week 12. At week 24, 1 patient in the 
zoledronic acid group and 0 patients in the alendronate group 
had NTX below the limit of detection. Reductions in serum 
C-terminal telopeptide of type I collagen (β-CTX) levels 
over time were similar to those observed for urine NTX. 
Zoledronic acid resulted in signiﬁ  cantly greater reductions 
in serum β-CTX levels at all post-baseline time points com-
pared to aledronate. At week 24, mean β-CTX was within 
the premenopausal reference range in the alendronate group 
and slightly below the reference range in the zoledronic acid 
group. Additionaly, the decline of serum beta-C-telopeptide 
of type I collagen (β-CTX) levels was greater for zoledronic 
acid in comparison with aledronate throughout the 24-week 
study, with levels remaining in the premenopausal range 
from week 12 to the end of the study. Additionally, bone-
speciﬁ  c alkaline phosphatase (BSAP) levels showed a more 
gradual reduction in both groups, reaching premenopausal 
range by week 12. According to this trial, a single infusion 
of zoledronic acid 5 mg leads to a greater and more rapid 
reduction in bone resorption markers compared to oral 
alendronate 70 mg, although they both have similar effects 
on bone formation.
A 1-year, randomized, double-blind, placebo-controlled 
trial by Reid et al included 351 postmenopausal women with 
low BMD who received placebo or 5 regimens of intravenous 
zoledronic acid (0.25 mg, 0.5 mg, or 1 mg at 3-month inter-
vals or a total annual dose of 4 mg or 2 doses of 2 mg each, 
6 months apart) (Reid et al 2002). The aim was to assess the 
effect of zoledronic acid on bone turnover and BMD. The 
increase in BMD was similar in all the zoledronic acid groups 
and ranged between 4.3% and 5.1% and between 3.1% and 
3.5% for the femoral neck compared to placebo. Biochemi-
cal markers of bone resorption were signiﬁ  cantly suppressed 
throughout the study in all zoledronic acid groups. According 
to this trial, annual infusions of zoledronic acid might be an 
effective treatment for postmenopausal osteoporosis, as they 
produce effects on bone turnover and bone density as great as 
those achieved with daily oral bisphosphonates with proven 
efﬁ  cacy against fractures.
A 5-year study by Devogelaer et al assessed the long-
term efﬁ  cacy and safety of prolonged use of zoledronic 
acid 4 mg for over 5 years (Devogelaer et al 2007). A single 
infusion of zoledronic acid 4 mg given once-yearly for 2, 3 
or 5 years was well tolerated with no evidence of excessive 
bone turnover reduction or any safety signals. Moreover, 
BMD increased signiﬁ  cantly, while bone turnover mark-
ers decreased from baseline and were maintained within 
premenopausal reference ranges.
The HORIZON recurrent fracture trial evaluated the 
fracture recurrence and mortality in patients receiving zole-
dronic acid (Lyles et al 2007). In this trial 1065 patients were 
assigned to receive yearly 5 mg of intravenous zoledronic 
acid, and 1062 patients were assigned to receive placebo. 
The infusions were ﬁ  rst administered within 90 days after 
surgical repair of a hip fracture. The aim was to evaluate the 
impact of zoledronic acid on new clinical fractures and the 
mortality after hip fracture. The rates of any new clinical 
fracture were 8.6% in the zoledronic acid group and 13.9% Clinical Interventions in Aging 2008:3(3) 449
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in the placebo group, indicating a 35% risk reduction with 
zoledronic acid. The respective rates of a new clinical verte-
bral fracture were 1.7% and 3.8%, and the respective rates of 
new nonvertebral fractures were 7.6% and 10.7%. Concern-
ing mortality there was a 28% reduction in deaths from any 
cause in the zoledronic acid group (p = 0.01). According to 
this study an annual infusion of zoledronic acid within 90 
days after repair of a low-trauma hip fracture was associated 
with a reduction in the rate of new clinical fractures and with 
improved survival.
Adverse events
In the HORIZON pivotal fracture trial no signiﬁ  cant dif-
ferences were observed with respect to the serious adverse 
events between patients receiving zoledronic acid and pla-
cebo, while most adverse events were mild to moderate. The 
incidence of all-cause mortality was 3.4% in the zoledronic 
acid group and 2.9% in the placebo group. A once-yearly 
infusion of zoledronic acid during a 3-year period was 
associated with a signiﬁ  cant and sustained decrease in the 
risk of vertebral, hip and other fractures (Black et al 2007). 
Taking that fractures are an important cause of disability 
and mortality among postmenopausal women, the use of 
zoledronic acid for treatment of postmenopausal osteoporosis 
is associated with improved survival (Lyles et al 2007). The 
incidence of serious adverse events in this trial was 30.1% 
and 29.2% for the zoledronic acid group and the placebo 
group respectively.
A statistically signiﬁ  cant higher rate of atrial ﬁ  brillation 
was recorded in the zoledronic acid group compared to 
placebo (1.3% and 0.5%, respectively). More women 
who received zoledronic acid intravenously developed 
serious atrial ﬁ  brillation compared to women who received 
placebo (Black et al 2007). However, the rates of all 
incidents of atrial ﬁ  brillation (serious plus nonserious) 
were not signiﬁ  cantly different between groups treated with 
zoledronic acid versus placebo. FDA (United States Food 
and Drug Administration) has reviewed the data about the 
possible association between zoledronic acid and atrial 
ﬁ  brillation and has not been able to identify a population of 
zoledronic acid users at increased risk for atrial ﬁ  brillation. 
Additionally, most incidents of this disorder take place more 
than 1 month after the infusion of the drug, by which time 
zoledronic acid is undetectable in the circulation. Also, in a 
subset of patients who were monitored by electrocardiogram 
up to the 11th day after infusion, there was no signiﬁ  cant 
difference in the prevalence of atrial ﬁ  brillation between 
patients who received zoledronic acid and those who 
received placebo. Until now, FDA has not decided how 
these data on atrial ﬁ  brillation should be interpreted and 
recommends that healthcare practitioners and patients 
should not change their prescribing practices on the use of 
zoledronic acid.
Zoledronic acid has been mainly associated with some 
postdose symptoms, including fever (18.1%), myalgia 
(9.4%), ﬂ  u-like symptoms (7.8%), arthralgia (6.8%), and 
headache (6.5%) (Black et al 2007). The above symptoms 
occur more often within the ﬁ  rst 3 days following zoledronic 
acid infusion, are mild and resolve within 3 days of the event 
onset. The above postdose symptoms can be reduced with 
the administration of acetaminophen or ibuprophen shortly 
after zoledronic acid infusion.
ONJ is a rare adverse event of zoledronic acid treatment 
which appears to occur more frequently with intravenous 
bisphosphonates compared to the oral regimens (Krueger 
et al 2007). The majority of the reported cases, however, 
were also receiving chemotherapy or corticosteroids. 
Furthermore, this adverse effect has been associated with 
invasive dental procedures, such as root canal or dental 
extraction. According to a retrospective study its preva-
lence in patients receiving bisphosphonates intravenously 
was 1 in 71.5. The review of 1951 medical records led to 
the identiﬁ  cation of 2 patients with ONJ who had received 
bisphosphonates. Both patients treated with bisphospho-
nates had multiple myeloma and were receiving monthly 
infusions (Murad et al 2007). In a prospective evaluation of 
252 cancer patients treated with bisphosphonates for 6 years 
the incidence of ONJ was 6.7% overall, 9.9% in myeloma 
6.5% in prostate cancer and 2.9% in breast cancer. The 
median number of infusions was 35 in the patients who 
developed ONJ compared with 15 for patients without 
ONJ (p  0.001) (Bamias et al 2005). As noted previously, 
length of exposure seems to be the most important risk 
factor for this adverse event and caution is required for 
use of bisphosphonates beyond 2 years (Body 2006). Kut 
et al, assessing the risk of this complication in oncologic 
patients, reported a prevalence of 1.5% (Kut et al 2004). In 
the Pivotal Fracture Trial (Black et al 2007) 7736 patients 
with postmenopausal osteoporosis were examined. Only 1 
patient treated with zoledronic acid and 1 patient treated 
with placebo developed symptoms consistent with ONJ, 
which resolved after appropriate treatment.
Other adverse events associated with zoledronic acid 
include local reactions at the infusion site such as itching, 
redness and/or pain which have been reported in 0.7% of 
patients receiving zoledronic acid intravenously (Black et al Clinical Interventions in Aging 2008:3(3) 450
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2007). Additionally, 0.2% of patients treated with zoledronic 
acid developed iritis, uveitis, episcleritis (Black et al 2007).
Zoledronic acid has been associated with renal dysfunc-
tion manifested as deterioration of renal function (increased 
serum creatinine) and in rare cases acute renal failure. In the 
HORIZON pivotal fracture trial, 1.8% of patients receiving 
zoledronic acid developed renal dysfunction, compared to 
0.8% in the placebo group. Severe renal dysfunction was 
rarely reported. In the same trial, 0.2% of the patients receiv-
ing zoledronic acid, primarily after the ﬁ  rst dose, developed 
a mild, asymptomatic decrease in calcium levels (less than 
1.87 mmol/L). Hypocalcemia is usually asymptomatic, but 
symptoms may include numbness or tingling sensations, 
especially in the area around the mouth, muscle spasms or 
muscle cramps.
Practice guidelines
The recommended dose for the treatment of postmenopausal 
osteoporosis is 5 mg of zoledronic acid in 100 mL ready 
to infuse solution. It is administered intravenously via a 
vented infusion line. The infusion time must not be less than 
15 minutes and the infusion rate should be constant. On the 
day of the infusion, patients may eat and drink normally. It 
is recommended that they drink at least 2 glasses of water 
(500 mL), before and after the infusion of zoledronic acid. 
Appropriate hydration is of great importance especially in 
patients receiving diuretic therapy.
Serum calcium levels and vitamin D levels should be 
assessed before treatment with zoledronic acid. Addition-
ally, renal function should be assessed and creatinine should 
be measured before treatment. It is also recommended that 
patients with possible risk factors (eg, cancer, chemotherapy, 
head and neck radiotherapy, corticosteroids, poor oral 
hygiene) should be subjected to a routine dental examination 
with appropriate preventive dentistry in order to avoid the 
rare possibility of ONJ.
It is strongly advised that patients treated with zoledronic 
acid receive adequate calcium and vitamin D supplementa-
tion especially in the days before and following the infusion. 
In the HORIZON pivotal fracture trial, patients received 
1000–1500 mg of elemental calcium as well as 400–1200 
IU of vitamin D supplements per day.
Contraindications refer to patients with hypersensitivity to 
this drug, or to any bisphosphonate or component of the con-
tainer. Zoledronic acid is not recommended for use in patients 
with severe renal impairment (creatinine clearance 30 mL/
min), in pregnant women, nursing mothers and in patients 
with noncorrected hypocalcemia at the time of infusion. 
Patients receiving zoledronic acid should not be treated with 
other bisphosphonates concomitantly.
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